ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Olon, an Italian pharmaceutical services firm with expertise in high-potency active ingredients, will begin manufacturing antibody drug conjugates (ADCs) with the construction of a new plant in Milan. The $23 million facility will be dedicated to manufacturing ultrapotent compounds, which are linked to antibodies as payloads for the production of ADCs. The company expects the first phase of the project, a payload R&D area, to be completed in the first half of 2024; a production line will be installed in a second phase.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X